No edit summary
Tag: Manual revert
 
(14 intermediate revisions by 9 users not shown)
Line 1: Line 1:
'''About biostealth''':
{{Cover Image|[[File:Biostealth Thesis cover image.jpg]]}}


biostealth is a London based Medical Technology startup focusing on the prevention and management of chronic respiratory conditions.
biostealth is a London based Medical Technology startup focusing on the prevention and management of chronic respiratory conditions.


'''biostealth’s vision:'''
== Team ==


Preventing premature death by continuously monitoring respiratory and cardiovascular health through everyday objects.
=== Lead PPG Engineer ===
Olivier Tsiakaka, Ph.D is a postdoctoral researcher at Université Laval and CERVO Brain Research Centre with extensive knowledge in optoelectronic systems and the novel use of Photoplethysmography (PPG) signals for medical technology applications.<ref name=":0">https://biostealth.ai/#index-team</ref>


'''Status on current round:'''
=== Operations Lead, China ===
Mohamed Alezzabi is a product R&D and Manufacturing expert in the Hardware, Automation/IoT and Grow related industries, having delivered 13 products from concept, to sample, to final production.<ref name=":0" />


Seeking to raise £600k for an 18-month runway.
=== Non-Executive Director ===
Andrew Davies is a commercialization expert specializing in the healthcare market, both capital & consumable, with broad marketing experience and an analytical approach to strategic planning coupled to innovative and creative marketing programs that increase business performance.<ref name=":0" />


<html>
=== CEO ===
<iframe width="560" height="315" src="https://www.youtube.com/embed/O_6Mt_8bjuw" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
Israel Ninsaw Gbati is an entrepreneur with a successful track record of generating revenue in his business ventures and an award-winning inventor who has also been recognized for his exceptional academic achievements.<ref name=":0" />
</html>


==Investment Interview==
=== COO ===
Georgios Papanikolaou is a healthcare technologist and respiratory health advocate promoting self-management education for chronic respiratory disease sufferers.<ref name=":0" />


'''Explain what your venture does.'''
=== Medical Doctor ===
Desmond Boakye Tanoh, M.D is an resident physician in internal medicine and lead researcher in cardiovascular pharmacology, bringing clinical experience to bear in team discussions and making sure the perspectives of chronic disease sufferers are included in the decision making process.<ref name=":0" />


At bioStealth, we are focused on preventing your premature death by continuously monitoring your respiratory and cardiovascular health through everyday objects.
== Other ==
To invest in or to contact the company, email support@biostealth.ai.


'''What stage is your business?'''
== References and notes ==
[[Category:Thesis]]
[[Category:Equities]]


We are getting ready to commence the next stage of testing - To test the product with 77 COPD patients.
__INDEX__
 
'''Give an overview of your startup's financing history.'''
 
We have self-funded the start-up with the help of family and friends.
 
'''Explain the ownership structure of your company.'''
 
Israel Ninsaw Gbati (Myself) - 65% George Papanikolaou - 35%.
 
'''How many employees do you have?'''
 
Israel Ninsaw Gbati (Myself) : Firmware Engineer, George Papanikolaou : Hardware Engineer Yun Jung Yeh : Product Designer and Market Researcher Mathys and Squire : Patent law firm TaxAssist Accountants : Accountancy firm.
 
We are also considering recruiting an additional person with specialized knowledge in high power electronics.
 
'''How much money are you seeking to raise in the current round?'''
 
£600,000.
 
'''Explain why you are raising finance.'''
 
This amount will give us enough fuel to launch our flagship product. This will allow us to : - employ a doctor, 1 additional software engineer(encryption expert), 1 additional hardware engineer(analog systems expert) , meet our R&D goals and marketing goals for the next 18 months.
 
'''Please explain the history of your venture.'''
 
The venture started in 2017. For my final year project I decided to find a way to monitor and detect early signs of respiratory and cardiovascular diseases which show no symptoms. This is how we stumbled upon the idea of ubiquitous health monitoring through everyday objects.
 
'''Please explain the longer term, future vision for the Company'''
 
We shall convert any object that you touch into an object that monitor your health. The next investment round shall be focused on securing enough funds to ensure rapid growth and global market penetration.
 
'''Explain the core technologies and/or service propositions of your venture.'''
 
We have invented something we call physiological surfaces. What we do is, we convert the surfaces of the objects that you hand comes in contact with into these physiological surfaces so that when you use these objects an assessment of your respiratory and cardiovascular health is taken.
 
'''Does your commercial strategy rely on intellectual property assets?'''
 
IP protection together with trade secrets is part of our business strategy. Our patent application is currently pending. We initially applied for PCT and then proceeded to apply in EU, U.S.A, GB and China. Our patent attorney is currently preparing a response to the search report.
 
'''What commercial progress have you made?'''
 
We are currently developing the COPD Management platform - Our flagship product is the Sree Mouse, a physiological tracking mouse that continuously measures and records the peripheral blood oxygen saturation, the heartbeat per minute and the heartbeat variability of users. These physiological parameters are some of the key parameters that people managing respiratory diseases have to keep track of to ensure they are maintained within certain limits. In preparation for the launch of this product we have created a Facebook page where we interact with over 1000 people currently managing COPD in the UK.

Latest revision as of 12:48, 19 August 2023

Biostealth Thesis cover image.jpg

biostealth is a London based Medical Technology startup focusing on the prevention and management of chronic respiratory conditions.

TeamEdit

Lead PPG EngineerEdit

Olivier Tsiakaka, Ph.D is a postdoctoral researcher at Université Laval and CERVO Brain Research Centre with extensive knowledge in optoelectronic systems and the novel use of Photoplethysmography (PPG) signals for medical technology applications.[1]

Operations Lead, ChinaEdit

Mohamed Alezzabi is a product R&D and Manufacturing expert in the Hardware, Automation/IoT and Grow related industries, having delivered 13 products from concept, to sample, to final production.[1]

Non-Executive DirectorEdit

Andrew Davies is a commercialization expert specializing in the healthcare market, both capital & consumable, with broad marketing experience and an analytical approach to strategic planning coupled to innovative and creative marketing programs that increase business performance.[1]

CEOEdit

Israel Ninsaw Gbati is an entrepreneur with a successful track record of generating revenue in his business ventures and an award-winning inventor who has also been recognized for his exceptional academic achievements.[1]

COOEdit

Georgios Papanikolaou is a healthcare technologist and respiratory health advocate promoting self-management education for chronic respiratory disease sufferers.[1]

Medical DoctorEdit

Desmond Boakye Tanoh, M.D is an resident physician in internal medicine and lead researcher in cardiovascular pharmacology, bringing clinical experience to bear in team discussions and making sure the perspectives of chronic disease sufferers are included in the decision making process.[1]

OtherEdit

To invest in or to contact the company, email support@biostealth.ai.

References and notesEdit